Abortion Care Awareness Act of 2025

The Abortion Care Awareness Act of 2025 mandates the Secretary of Health and Human Services to implement a national public health education and awareness campaign. This campaign focuses on enhancing access to abortion and related health services, including information on medication abortion (mifepristone and misoprostol), telehealth options, legal rights for interstate travel for care, and how to differentiate legitimate providers from crisis pregnancy centers. The bill does not appropriate new federal funds for these services, nor does it change the legal landscape of abortion access. Its impact is limited to increasing public knowledge of existing services and providers, which will translate into a slight increase in demand for these services. The money trail for this bill is indirect. The campaign itself will be funded through existing HHS budgets, meaning no new direct appropriations for the campaign are specified. However, the increased awareness will drive demand for services already provided by healthcare entities. Pharmacies like CVS Health ($CVS) and Walgreens Boots Alliance that dispense medication abortion drugs will see a marginal increase in prescription volume. Healthcare staffing companies such as AMN Healthcare Services ($AMN) may experience a minor uptick in demand for specialized personnel in areas where access increases. Diagnostic companies like Laboratory Corporation of America Holdings ($LH) and Quest Diagnostics ($DGX) could see a slight increase in related testing services. Pharmaceutical companies that manufacture mifepristone and misoprostol, such as Perrigo Company plc ($PRGO), Viatris Inc., and Teva Pharmaceutical Industries Ltd. ($TEVA), will benefit from increased utilization. Historically, federal public health campaigns have shown varied impacts on specific market segments. For instance, the Affordable Care Act's public awareness campaigns in 2013-2014 led to increased enrollment in health plans, benefiting insurers like UnitedHealth Group ($UNH) and Anthem (now Elevance Health, $ELV) with a modest 2-3% increase in membership-related revenue in subsequent quarters. However, this bill's scope is narrower, focusing on awareness rather than direct provision or funding of services, thus limiting the magnitude of market impact. There is no direct historical precedent for a federal campaign specifically on abortion access awareness at this scale, making direct market comparisons challenging. Specific winners include pharmacies like CVS Health ($CVS) and Walgreens Boots Alliance due to increased dispensing of medication abortion drugs. Pharmaceutical manufacturers of mifepristone and misoprostol, such as Perrigo Company plc ($PRGO), Viatris Inc., and Teva Pharmaceutical Industries Ltd. ($TEVA), will see a slight increase in product demand. Healthcare providers offering these services will experience higher patient volumes. Losers are not directly identifiable as the bill does not restrict or penalize any existing entities; rather, it aims to inform the public about available services. This bill has been introduced in the House and referred to the Committee on Energy and Commerce. Given the current political climate, its passage through both chambers is uncertain. If it passes, the HHS Secretary would then be directed to implement the campaign, which would likely take 6-12 months to fully roll out after enactment. The earliest market impact would be observed in late 2025 or early 2026.